Solventum (SOLV) Q2 2026 earnings summary

Executive summary

• Q2 2026 sales reached $2.21 billion, up 2.2% year-over-year, with 9.5% organic growth driven by strong execution, volume, and product mix, including advanced orders ahead of ERP cutovers.

• Announced intent to separate the Health Information Systems (HIS) business to sharpen MedTech focus, with separation workstreams progressing and multiple interested parties.

• Transformation initiatives, including the nearing completion of the 3M separation and winding down of prior workstreams, are advancing.

• Innovation and commercial focus are driving adoption of new products and under-penetrated solutions in core markets.

• Increased full-year 2026 guidance for organic sales growth, adjusted EPS, and free cash flow.

Financial highlights

• Q2 2026 sales were $2.21 billion, up 2.2% reported and 9.5% organic year-over-year; gross margin was 60.1% (including tariff refund), 55.6% excluding refund.

• Adjusted operating income margin was 28.4%; GAAP operating margin was 8.2% due to higher SG&A and legal charges.

• Adjusted EPS was $2.55, including $0.34 from advanced orders and $0.48 from tariff refunds; GAAP EPS was $0.53.

• Free cash flow was $144 million, above expectations due to timing of tax payments and insurance proceeds.

• Recognized a $100 million pre-tax benefit from tariff refunds and $125 million in advanced customer orders ahead of ERP deployment.

Outlook and guidance

• Raised 2026 organic sales growth guidance to 2.5%-3% (ex-SKU exits: 3.5%-4%).

• Adjusted EPS guidance increased to $7.10-$7.20 (prior: $6.40-$6.60), including $0.48 for tariff refund.

• Free cash flow guidance raised to $200-$300 million, with most expected in Q4.

• Operating margin guidance raised to 22.2%-22.7%, reflecting the full tariff refund benefit.

• Q3 expected to see reversal of $125 million advanced order benefit from Q2.